ArticleAnnals of surgical oncology2025
Prognostic Value of a ≥ 1000 μm Posterior Margin After Gerota's Fascia Resection in Distal Pancreatectomy for Resectable Pancreatic Cancer: A Single-Center Retrospective Study.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadical antegrade modular pancreatosplenectomy (RAMPS) enables posterior dissection along Gerota's fascia, contributing to improved R0 resection rates, lymphadenectomy, and overall survival (OS) in pancreatic body and tail cancers. Although a posterior margin ≥ 1000 μm has been associated with better prognosis, its relative impact compared with Gerota's fascia resection remains unclear. This study evaluated whether securing a posterior margin ≥ 1000 μm improves outcomes in patients undergoing Gerota's fascia resection for pancreatic body and tail cancer.
methodsThis retrospective study included 93 patients who underwent distal pancreatectomy with Gerota's fascia resection for resectable pancreatic cancer without adrenal or kidney invasion (2014-2022). Clinical data, recurrence-free survival (RFS), and OS were compared between patients with posterior margins < 1000 μm and ≥ 1000 μm. Multivariate regression analysis identified independent predictors of recurrence.
resultsOf 93 patients, 21 (23%) had posterior margins < 1000 μm and 72 (77%) had margins ≥ 1000 μm. OS and recurrence rates at 1, 3, and 5 years were comparable between the < 1000 μm and ≥ 1000 μm groups, with no significant differences (OS: 85%, 63%, 51% vs. 93%, 68%, 53%, p = 0.65; recurrence: 7.0%, 33.5%, 59.1% vs. 19.0%, 44.4%, 66.6%, p = 0.30). Multivariate analysis identified four or more positive lymph nodes, splenic vessel invasion, and elevated tumor markers as independent recurrence risk factors.
conclusionsIn resectable pancreatic cancer without adrenal or kidney invasion, a posterior margin ≥ 1000 μm was not associated with improved survival, supporting the adequacy of this approach. Further investigation into systemic disease control via preoperative chemotherapy is warranted.
Indexed as
Identifiers
40903710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.